Insights on T-DXd and Emerging Research on ADCs in HR+/HER2-Low Breast Cancer
June 27th 2024Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, share advice for community oncologists on the utilization of T-DXd and discuss the future outlook for antibody-drug conjugates in HR+/HER2-low breast cancer.
Watch
Best Candidates for HER2-Directed ADCs in HR+/HER2-Low Metastatic Breast Cancer
June 27th 2024Experts on breast cancer describe the best candidates for HER2-directed antibody-drug conjugates in HR+/HER2-low metastatic breast cancer, highlighting the role of trastuzumab deruxtecan in later lines of therapy.
Watch
Current treatment options for ccRCC based on patient and disease factors
June 26th 2024Matthew Campbell, MD, MS, and Rana McKay, MD, offer a concise review of existing treatment approaches for clear cell renal cell carcinoma across risk categories, along with considerations for sequencing therapies.
Watch
Study Evaluates Methods for Breast Cancer Recurrence Surveillance
June 26th 2024Ali Duffens, MD, discusses a study in which investigators assessed the mode of detection for breast cancer recurrence within an integrated health system by assessing the utility and outcomes of current surveillance guidelines recommended by the National Comprehensive Cancer Network.
Watch
ADRIATIC Study Shows Benefit of Consolidation Durvalumab in LS-SCLC
June 25th 2024Missak Haigentz, MD, discusses the impact of the results from the ADRIATIC study of durvalumab as consolidation treatment after concurrent chemoradiation for the treatment of patients with limited-stage small cell lung cancer.
Watch
Efficacy Outcomes from CARTITUDE-4 in Relapsed/Refractory Multiple Myeloma
June 24th 2024A myeloma specialist reviews the latest efficacy outcomes from the CARTITUDE-4 trial evaluating cilta-cel in patients with relapsed/refractory multiple and discusses how the results are informing treatment decisions.
Watch
CAR T-Cell Therapy Referral Process in Early Relapsed/Refractory Multiple Myeloma
June 24th 2024A medical oncologist discusses the referral process for patients being considered for CAR T-cell therapy in early relapsed/refractory multiple myeloma, highlighting factors that inform treatment selection.
Watch
Current Treatment Options for Non-Clear Cell Renal Cell Carcinoma
June 24th 2024A genitourinary oncologist discusses current treatment options available for patients with non–clear cell renal cell carcinoma and discusses the roles of tyrosine kinase inhibitors (TKIs), PD-1 inhibition, and combination therapy.
Watch